OBJECTIVES: To estimate the cost per sustained virological response (SVR) in genotype 1 (G1) hepatitis C (HCV) patients according to previous treatment response and METAVIR groups in Brazil. METHODS: SVR and extended rapid virological response (eRVR) rates were from the respective phase III clinical trials of telaprevir (ADVANCE and REALIZE) and boceprevir (SPRINT-2 and RESPOND-2) for treatment naive patients, METAVIR F0-F3 naive patients, and treatment experienced patients (relapsers, partial responders and null responders). When SVR and eRVR rates were not available for a patient subgroup these were assumed to be the same as the global patient population. Brazilian treatment costs were based on the eRVR rates and calculated based on the prices for telaprevir and boceprevir recently published by the HTA body CONITEC. Treatment costs for pegylated interferon and ribavirin were calculated from the reimbursed price published in the official website: www.comprasnet.gov.br. RESULTS: Telaprevir has the lowest cost-SVR for all patients in the analysis compared to boceprevir. In treatment naive patients, telaprevir has a cost-SVR of R$ 64.513 compared to boceprevir with R$ 72.275. In METAVIR scale of F0-F3 treatment naive patients, telaprevir has a lower cost-SVR of R$ 64.196, while the cost-SVR for boceprevir remains 12% higher (R$ 72.275). The lowest cost-SVR was observed for the prior relapse patients treated with telaprevir, R$ 51.283/SVR, compared to boceprevir with R$ 58.736/SVR. Boceprevir has the highest cost-SVR at R$ 90.658 compared to R$68.144 with telaprevir for patients with a previous partial response. For prior null-responders, telaprevir is the only option since as these patients were not studied with boceprevir. CONCLUSIONS: Telaprevir has the lowest cost-SVR compared to boceprevir for the treatment of hepatitis C G1 patients in Brazil regardless of baseline disease severity and prior treatment response.